Merck Sharp + Dohme Corp.

Sanofi

Ra Pharmaceuticals, Inc.

Janssen Biotech, Inc.

Protagonist Therapeutics, Inc.

Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.a.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

Istituto De Ricerche Di Biologia Molecolare P. Angeletti Spa.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Msd Italia S.r.l.

Raffaele Ingenito

Elisabetta Bianchi

Alessia Santoprete

Danila Branca

Thomas Joseph Tucker

Yusheng Xiong

Angela Dawn Kerekes

Hyewon Youm

Chengwei Wu

Alonso Ricardo

Olivier Duclos

Sergio Mallart

Nicolas Cedric Boyer

Sookhee Nicole Ha

Aurash Shahripour

Stéphane Illiano

Willy Costantini

Paola Magotti

Claire Minoletti-Hochepied

Philip Jones

Rita Scarpelli

Eric J Gilbert

Zhong Ma

Mark W Embrey

Frank Marguet

Ketki Ashok Dhamnaskar

Jesus Maria Ontoria Ontoria

Immacolata Conte

Stefania Colarusso

Laura Llauger Bufi

Derek M LaPlaca

Joseph R Stringer

Roberto Costante

Hubert B Josien

Michael Rowley

Fa-Xiang Ding

Ashok Bhandari

Brian Troy Frederick

Giovanna Pescatore

Abbas M Walji

Olaf Kinzel

Federica Ferrigno

Carsten Schultz-Fademrecht

Barbara Attenni

Chengzao Sun

Sandeep Somani

Raymond Patch

Carsten Schultz

Jesus Maria Ontoria

Gregory Thomas Bourne

The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.

Cyclic polypeptides for PCSK9 inhibition

A biologically active single chain Relaxin peptide having the formula N-Ac-L-E-G-R-E-K-V-R-A-X-I-X-X-E-G-X-S-T-F-S-X-R-A-X-NH-C, or a salt of solvate thereof, is described.

Modified lipidated relaxin B chain peptides and their therapeutic use

Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R, and Rare as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions 

PCSK9 antagonists bicyclo-compounds

Provided is a biologically active single chain Relaxin peptide having the following formula (I):N-Ac-(E)-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-R-(X)-(X)-(K)-(X)-(gE)-X-C; or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.

Modified lipidated Relaxin B chain peptides and their therapeutic use

Provided is a biologically active single chain Relaxin peptide having the following formula (I): N-X-(E)-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-R-(X)-(X)-(X)-NH-C. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof. Further provided is the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition for use as a medicament.

Modified relaxin B chain peptides and their therapeutic use

Provided is a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): N-Ac-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-X-X-X-NH-Cor a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one biologically active single chain Relaxin peptide. Uses of the peptide or the pharmaceutical composition as a medicament are also provided.

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma. 

Heterocycle substituted ketone derivatives as histone deacetylase (HDAC) inhibitors

The present invention relates to compounds of formula I: or pharmaceutically acceptable salts or tautomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.

Heterocycle derivatives as histone deacetylase (HDAC) inhibitors

Growing community of inventors

Pomezia, Italy

Raffaele Ingenito